Methods | Parallel, double‐blind | |
Participants | 496 participants with moderate‐severe asthma (based on at least medium‐dose ICS, inadequate control ACQ ≥ 1.5)
|
|
Interventions | IV reslizumab 3.0 mg/kg or placebo once every 4 weeks (total of 4 doses) | |
Outcomes | Primary outcomes
Secondary outcomes
|
|
Notes | 66 study locations across the USA Funding: Teva Branded Pharmaceutical Products R&D, Inc |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not stated, no clarification available from study authors |
Allocation concealment (selection bias) | Unclear risk | Not stated, no clarification available from study authors |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Double blind |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Double blind |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Dropouts comparable in each group (16/98, 16%, placebo vs 58/398, 15%, reslizumab) |
Selective reporting (reporting bias) | Low risk | All primary and secondary outcomes reported with numbers, except blood eosinophil counts only shown as a chart |